For 16 years, Arkana has delivered exceptional patient care, research and education with one thought in mind: the more we all learn, the more we can do.
Led by Director Patrick D. Walker, M.D., our 19 fellowship-trained pathologists have decades of experience interpreting biopsies.
Arkana is committed to providing doctors with the highest quality, clinico-pathologic discussion possible. We recognize that in order to best serve the needs of our clinicians we must work together with them, not just as a lab, but as an extension of their practice. It is our goal to help equip doctors with the results they need to deliver the most effective patient care possible. As pathologists, we recognize that the longest period in a patient’s life is the timeframe between the day he/she has a biopsy and the day the result arrives.
When we opened our doors in 2001, we already had a top-notch physician and researcher in Arkana’s founder, Dr. Patrick Walker. Dr. Walker began reading renal biopsies in 1978. For the next twenty-three years he worked in university settings where he read biopsies, did research, and taught. Following his desire to focus exclusively on kidney disease, he opened Nephropath and surrounded himself with physicians and staff who shared his vision.
Research, education and innovation are hardwired into Arkana’s culture. But what makes our practice indispensable to nephrologists around the US is the high level of interaction with the pathologists who read the biopsies. Today, just as we did on day one, the pathologist that reads your case is the pathologist that calls you to discuss the results.
Over the last few years our curiosity, innovations and growing team of doctors — the finest and most concentrated in the field anywhere in the world — have all contributed to a constantly expanding practice. Today we provide renal pathology, serology, neuropathology, and molecular (genomic) services. We’ve doubled down on our commitment to research and teaching. We’ve recently added a world-class zebrafish research lab. We are actively working toward the day that our research yields breakthroughs that make our services unnecessary. Eradicating rare and common diseases is the end game of all of our efforts, because patient health is foremost in our minds every day.